These findings are consistent with those of previous studies showing that patients who have MPN with type 1-like CALR mutation are associated with a myelofibrosis phenotype and those with type 2-like mutation are mainly associated with an ET phenotype [6,9]. This evidence concerns the gene CALR and myeloproliferative disorder.